Sucampo Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Mizuho Securities Reiterates Buy on Sucampo Pharma (SCMP) as Amitiza Royalies Drives 2Q Beat
August 3, 2016 9:12 AM EDTMizuho Securities reiterated a Buy rating and $14.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 2Q earnings report. SCMP reported revenues of $52.0M and $0.23 in EPS vs. consensus of $48.6M and $0.22. The beat was driven primarily by higher royalty revenue from Amitiza... More
Sucampo Pharma (SCMP) Tops Q2 EPS by 1c
August 3, 2016 8:09 AM EDTSucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.23, $0.01 better than the analyst estimate of $0.22. Revenue for the quarter came in at $52 million versus the consensus estimate of $48.61 million.
For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.
... More